Corcept rises after FDA approves ovarian cancer drug

Shares of drugmaker Corcept Therapeutics CORT.O rise 27.4% to $43.09

Stock set for biggest daily percentage rise in nearly a year, if gains hold

U.S. Food and Drug Administration approves co's drug, relacorilant, branded as Lifyorli, for an aggressive form of ovarian cancer

Agency says drug is to be used in combination with a chemotherapy drug, nab-paclitaxel, for the treatment of platinum-resistant epithelial ovarian cancer, a type of cancer that returns or continues to grow within about six months after treatment with platinum-based chemotherapy

FDA's approval was based on a 381-patient trial, where participants on the combination therapy lived a median of 16 months, compared with 11.9 months on chemotherapy alone

Lifyorli works by blocking cortisol-related signals, which can help make tumors more responsive to chemotherapy

CORT fell more than 30% in 2025